Insulin resistance is a physiological state in which cells and tissues respond less effectively than normal to insulin. The major tissues involved are skeletal muscle, adipose tissue and liver, although insulin resistance can affect multiple metabolic pathways throughout the body. A given concentration of insulin therefore produces a smaller biological effect than it would in a more insulin-sensitive state.
The pancreas can initially compensate by producing and releasing more insulin, meaning a person can have insulin resistance without immediately having high blood glucose. As compensation becomes insufficient, glucose concentrations begin to rise. Insulin resistance is therefore best understood as impaired insulin action rather than simply “having too much insulin” or “having high blood sugar”.
In skeletal muscle, insulin resistance primarily impairs insulin-stimulated glucose uptake and downstream metabolic responses. After eating, insulin normally helps muscle cells increase glucose uptake and store some glucose as glycogen. With insulin resistance, this response is reduced, so more glucose remains in the circulation and the pancreas must secrete more insulin to obtain an equivalent effect.
In the liver, insulin resistance can impair insulin's ability to suppress hepatic glucose production, allowing the liver to continue releasing glucose even when glucose availability is already adequate. In adipose tissue, impaired insulin action can reduce suppression of lipolysis, potentially increasing the circulation of free fatty acids. These tissue-specific defects interact rather than occurring as completely separate processes.
A defining feature of early insulin resistance is compensatory hyperinsulinaemia, meaning increased circulating insulin concentrations caused by increased pancreatic secretion. The pancreas can often maintain relatively normal blood glucose for years by increasing insulin output. This is one reason insulin resistance may remain clinically silent. Eventually, however, pancreatic beta cells may not be able to maintain sufficient insulin secretion relative to the degree of resistance. Glucose then rises, first into ranges classified as prediabetes and, if sufficiently high or persistent, into ranges meeting criteria for diabetes. The transition is not necessarily abrupt; it can develop gradually through changing relationships between insulin sensitivity, beta-cell function and glucose levels.
Insulin resistance is closely associated with the metabolic syndrome, although the terms are not interchangeable. Metabolic syndrome refers to a cluster of cardiovascular and metabolic risk factors that can include increased waist circumference, elevated blood pressure, abnormal triglycerides, low HDL cholesterol and elevated blood glucose. Insulin resistance is one underlying physiological process that may contribute to several of these abnormalities. It is also strongly associated with excess adiposity, particularly accumulation of visceral or abdominal fat, but body size alone does not define insulin resistance and people with lower body weight can also develop it. Conversely, not everyone with excess body fat has identical degrees or patterns of insulin resistance.
Insulin resistance is distinct from type 1 diabetes. Type 1 diabetes is primarily characterised by autoimmune destruction of pancreatic beta cells and consequent insulin deficiency, whereas insulin resistance is a central feature of type 2 diabetes. A person with type 1 diabetes can develop insulin resistance as well, particularly if other risk factors are present, so the concepts are not mutually exclusive. Likewise, insulin resistance is not itself equivalent to diabetes. It can occur before diabetes and may be present for a substantial period while glucose remains below the diagnostic threshold. This distinction is clinically important because diabetes is diagnosed from blood glucose or HbA1c criteria rather than from the presence of insulin resistance alone.
The mechanisms underlying insulin resistance are complex and involve interactions between genetics, adipose tissue biology, liver metabolism, muscle metabolism, physical activity, diet, sleep, hormonal signals and inflammatory processes. At the cellular level, impaired insulin receptor signalling can reduce downstream activation of pathways responsible for glucose transport and metabolic regulation. Excess lipid accumulation within tissues, altered adipokine signalling and inflammatory mediators have all been implicated in insulin-resistant states. The precise contribution of each mechanism differs between individuals and conditions. This complexity explains why there is no single laboratory test or single cause that accounts for every case. Insulin resistance is a physiological phenotype arising from several interacting mechanisms rather than one uniform disease.
Clinicians generally do not diagnose insulin resistance simply from a person's symptoms because it often produces no specific symptoms. Research settings can measure insulin sensitivity using sophisticated methods such as the hyperinsulinaemic-euglycaemic clamp, while simpler surrogate measures can use fasting glucose and insulin. In routine clinical practice, however, attention commonly focuses on consequences and associated conditions such as prediabetes, type 2 diabetes, abnormal lipids, high blood pressure and excess adiposity. A normal blood glucose result does not necessarily prove that insulin sensitivity is optimal, because the pancreas may be compensating by producing more insulin. Conversely, a single insulin measurement is difficult to interpret without appropriate clinical and laboratory context.
Insulin resistance matters because it can contribute to progressively impaired glucose regulation and increase the likelihood of type 2 diabetes. It is not necessarily irreversible at every stage: improvements in physical activity, body composition where relevant, dietary pattern, sleep and other health factors can improve insulin sensitivity, and treating associated conditions can reduce metabolic risk. The NHS notes that type 2 diabetes can sometimes be prevented or put into remission through measures including weight loss and dietary improvement. These effects do not mean that every individual can eliminate insulin resistance completely, because genetic, hormonal and disease-related factors can continue to influence insulin action.
